An update from Dynavax ( (DVAX) ) is now available.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company also secured a $30 million contract with the U.S. Department of Defense to advance its plague vaccine program. The financial growth strengthens Dynavax’s market position, allowing it to focus on strategic growth pillars, including maximizing HEPLISAV-B’s market share and advancing its clinical pipeline.
More about Dynavax
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that develops and commercializes innovative vaccines to protect against infectious diseases. The company has two commercial products: HEPLISAV-B vaccine, approved for preventing hepatitis B infection in adults, and the CpG 1018 adjuvant, used in HEPLISAV-B and multiple COVID-19 vaccines.
YTD Price Performance: -2.09%
Average Trading Volume: 2,208,888
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $1.66B
See more data about DVAX stock on TipRanks’ Stock Analysis page.
